Search

Jennifer Logue, MD

Medical Director, Apheresis for Malignant Hematology and Cellular Therapy

Bone Marrow Transplant
Jennifer Logue
Jennifer Logue
Locations

Memorial Cancer Institute

12235 Pines Boulevard
Pembroke Pines, FL 33026

Phone: 954-265-4325

Fax: 954-276-0345

Get Directions

Memorial Cancer Institute

1750 East Hallandale Beach Boulevard
Hallandale, FL 33009

Phone: 954-265-4325

Fax: 954-276-0765

Get Directions

About Me

Medical Director, Apheresis for Malignant Hematology and Cellular Therapy

I am a hematologist specializing in bone marrow transplants at Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System. I am also the medical director of Apheresis for the Malignant Hematology and Cellular Therapy program. Apheresis is the process we use to collect blood or stem cells from a patient or donor to be used for cellular therapy.

I treat patients with any hematologic malignancy who may benefit from allogeneic bone marrow transplant, autologous bone marrow transplant, or chimeric antigen receptor (CAR) T-cell therapy. Currently we offer CAR T-cell therapy for lymphoma and B-cell acute lymphoblastic leukemia (B-ALL), and we will soon be able to offer CAR-T for multiple myeloma. I also treat lymphoma and multiple myeloma with non-cellular therapies.

I studied genetics in college and fell in love with the biology of cancer. There are many overlapping processes within a cell that attempt to safeguard the cell's ability to copy itself perfectly time after time, but cancer cells find ways to disrupt that process and grow out of control. In 2023, many of the immunotherapies we now have in our cancer-fighting "toolbelt" act directly on these genetic pathways at points that have become dysregulated due to an individual's specific tumor biology. This allows us to provide targeted and personalized treatments. It’s an exciting time to be involved in oncology.

The process of planning, organizing, undergoing, and then recovering from any cellular therapy can be difficult and scary for patients. I love working in cellular therapy because it is a treatment that can potentially offer patients a cure, even for aggressive, refractory diseases. My role is to educate you about your disease and help you make the best treatment decision to align with your personal goals.

In bone marrow transplant and cellular immunotherapy, we work as a team to compassionately guide our patients through these complex processes and are with you every step of the way to offer support and hope. My belief is that the better we understand each other and the situation, the better you will feel physically, emotionally, and spiritually. 

 

Education

Fellowships

  • H Lee Moffit Cancer Ctr & Research Inst @ Usf, 2021, Oncology and Hematology
  • H Lee Moffit Cancer Ctr & Research Inst @ Usf, 2022, Bone Marrow Transplant
  • H Lee Moffit Cancer Ctr & Research Inst @ Usf, 2022, Bone Marrow Transplant

Residency

  • Wake Forest University, 2018

Medical Education

  • Boston University, 2015

Certifications

  • American Board of Internal Medicine-Hematology
  • American Board of Internal Medicine-Internal Medicine

Awards, Achievements, and More

Publications

Please view Dr. Jennifer Logue’s publications on PubMed.

Professional Organizations

  • American Society for Apheresis
  • American Society for Transplantation and Cellular Therapy
  • American Society of Clinical Oncology
  • American Society of Hematology
  • Florida Society of Clinical Oncology
  • Society for Immunotherapy of Cancer

Presentations

  • Hansen DK, Peres L, Freeman C, et al. (February, 2023). Baseline Levels of Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel. Tandem Meetings of ASTCT and CIBMTR; Orlando, FL, USA.

  • Ionescu F, Freeman C, Castaneda O, et al. (February, 2023). Fludarabine Exposure Impact on Safety and Efficacy of Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM). Tandem Meetings of ASTCT and CIBMTR; Orlando, FL, USA.

  • Mohty R, Drekolias D, Peres L, et al. (February, 2023). Hematopoietic Recovery after Anti-B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T Cell Therapy (CAR T), Idecabtagene Vicleucel (Ide-cel), for Relapsed/Refractory Multiple Myeloma (RRMM). Tandem Meetings of ASTCT and CIBMTR; Orlando, FL, USA.

  • Rejeski K, Hansen DK, Bansal R, et al. (December, 2022). The CAR-Hematotox Score as a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma. Annual Meeting of the American Society of Hematology; New Orleans, LA, USA.

  • Jim HSL, Hoogland AI, Logue JL, et al. (December, 2022). Real-World Patient-Reported Outcomes Among Recipients of Axicabtagene Ciloleucel for Relapsed/Refractory Large B Cell Lymphoma. Annual Meeting of the American Society of Hematology; New Orleans, LA, USA.

  • Logue JM, Shrewsbury AM, Peres LC, et al. (May, 2022). Cytopenia and Infection Early after Standard of Care Idecabtagene Vicleucel in Multiple Myeloma. Moffitt Scientific Symposium; Tampa, FL, USA.

  • Logue JM, Shrewsbury AM, Peres LC, et al. (April, 2022). Cytopenia and Infection Early after Standard of Care Idecabtagene Vicleucel in Multiple Myeloma. Tandem Meetings of ASTCT and CIBMTR; Salt Lake City, UT, USA.

  • Hansen DK, Shrewsbury AM, Peres L, et al. (April, 2022). Marrow Myeloma Burden and Idecabtagene Vicleucel Outcomes in the Standard of Care Setting. Tandem Meetings of ASTCT and CIBMTR; Salt Lake City, UT, USA.

  • Hansen DK, Shrewsbury AM, Peres L, et al. (April, 2022). Impact of Obesity on Lymphodepletion and Outcomes Following Idecabtagene Vicleucel. Tandem Meetings of ASTCT and CIBMTR; Salt Lake City, UT, USA.

  • Barata A, Hoogland AI, Kommalapati A, Logue J, Hyland K, Eisel SL, Small BJ, Welniak T, Irizarry-Arroyo N, Rodriguez Y, Jayani RV, Booth-Jones M, Oswald LB, Gonzalez BD, Kirtane KS, Jain MD, Mohktari S, Chavez JC, Lazaryan A, Shah BD, Locke FL, Jim SLH. (December, 2021). Change in Patients’ Perceived Cognition Among Chimeric Antigen Receptor T-Cell Therapy Recipients at Day 360. Annual Meeting of the American Society of Hematology; Atlanta, GA, USA.

  • Logue JM, Shrestha B, Hendricks J, Diaz-Rijo J, Yu B, Kroeger J, Zhang S, Cubitt C, Davila ML. (May, 2020). Identification of immune targets for development of a multi-antigen T cell therapy for AML. Moffitt Scientific Symposium; Tampa, FL, USA.

  • Logue JM, Krivenki GS, Larson V, Bachmeier CA, Chavez JC, Davila ML, Khimani F, Lazaryan A, Liu HD, Pinilla-Ibarz J, Shah BD, Dholaria BR, Jain MD, Locke FL. (May, 2019). Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL). American Society of Clinical Oncology; Published online via Journal of Clinical Oncology 37(15).

  • Logue JM, Krivenki GS, Larson V, Bachmeier CA, Chavez JC, Davila ML, Khimani F, Lazaryan A, Liu HD, Pinilla-Ibarz J, Shah BD, Dholaria BR, Jain MD, Locke FL. (May, 2019). Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL). Moffitt Scientific Symposium; Tampa, FL, USA.

  • Logue JM, Qasem S, Miller L, Watabe K, Su J, Laxton AW, Tatter SB, Chan MD, Ruiz J. (May, 2017). A Genetic Signature for Predicting Brain Metastasis Recurrence after Stereotactic Radiosurgery. Wake Forest Department of Internal Medicine Research Symposium; Winston Salem, NC, USA.

  • Batt K, Logue JM, Imboden L, Smith A, Bonomi M. (May, 2017). Eradicating an Old Inhibitor: Elimination of a Factor VIII inhibitor in a Patient with Hemophilia A. Wake Forest Department of Internal Medicine Research Symposium; Winston Salem, NC, USA.

  • Logue JM, Qasem S, Miller L, Watabe K, Su J, Laxton AW, Tatter SB, Chan MD, Ruiz, J. (February, 2017). A Genetic Signature for Predicting Brain Metastasis Recurrence after Stereotactic Radiosurgery. American College of Physicians North Carolina Annual Chapter Scientific Meeting; Durham, NC, USA.

  • Logue JM, Qureshi MM, Zaner KS, Cooley TP, Jalisi S, Truong MT. (September, 2013). The Evaluation of Chemoradiotherapy Toxicity and Outcome in Head and Neck Cancer. American Society for Radiation Oncology; Atlanta, GA, USA.

  • Logue JM, Qureshi MM, Zaner KS, Cooley TP, Jalisi S, Truong MT. (February, 2013). The Evaluation of Chemoradiotherapy Toxicity and Outcome in Head and Neck Cancer. Medical Student Summer Research Symposium; Boston, MA, USA.

  • Logue JM, Demarco RS, Lundquist EA. (April, 2011). Protein Kinase C interacts with Rac GTPases in the control of the actin-binding protein UNC-115/abLIM in Caenorhabditis elegans axon pathfinding. University of Kansas Undergraduate Research Symposium; Lawrence, KS, USA.

  • Logue JM, Ahn Y, Krumlauf R. (July, 2010). Function of Wise/Sostdc1 in murine mammary gland development. Stowers

Hospital Affiliations